


Appl. No. 10/018,617
 Amdt. dated
 Reply to Office Action of May 7, 2003

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS:

Claim 1 (cancelled): A compound that is 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt of Formula II:



wherein R₁ is H or lower alkyl and x is a number from 0 to 10.

Claim 2 (cancelled): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt.

Claim 3 (cancelled): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt hydrate.

Claim 4 (original): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 1 having an x-ray powder diffraction pattern substantially comprising:

Appl. No. 10/018,617

Amdt. dated

Reply to Office Action of May 7, 2003

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.760	13.0648	5106	100.0	1497	100.0	0.234
2	8.183	10.7953	1743	34.1	435	29.1	0.200
3	8.560	10.3207	1866	36.5	543	36.3	0.233
4	9.239	9.5638	234	4.6	29	1.9	0.096
5	9.760	9.0546	972	19.0	220	14.7	0.181
6	10.569	8.3634	156	3.1	12	0.8	0.061
7	11.141	7.9353	178	3.5	29	1.9	0.130
8	13.760	6.4304	266	5.2	46	3.1	0.138
9	15.599	5.6761	338	6.6	63	4.2	0.148
10	16.740	5.2917	433	8.5	64	4.3	0.118
11	17.420	5.0866	1890	37.0	689	46.0	0.291
12	20.639	4.3000	523	10.2	128	8.5	0.196
13	21.391	4.1505	188	3.7	20	1.3	0.085
14	22.139	4.0119	445	8.7	74	4.9	0.132
15	31.559	2.8326	270	5.3	24	1.6	0.070

Claim 5 (currently amended): The compound ~~6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt~~ crystalline compound of claim 4 having a ^{13}C NMR (solid state) in ppm of: 189.6; 186.2; 71.4; 43.4; 30.1; 28.4; 25.2; 23.1.

Claim 6 (currently amended): The compound ~~6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt~~ crystalline compound of claim 4 having a ^{13}C NMR peak at 25.2 ppm.

Claim 7 (cancelled): The crystalline compound of Claim 1, wherein said compound comprises 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid mono-calcium salt ethanol solvate, wherein R_1 is ethyl.

Appl. No. 10/018,617
 Amdt. dated
 Reply to Office Action of May 7, 2003

Claim 8 (original): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt ethanol solvate having an x-ray powder diffraction pattern substantially comprising:

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.899	12.8028	13186	100.0	3025	100.0	0.184
2	8.261	10.6945	5221	39.6	931	30.8	0.143
3	8.838	9.9969	2057	15.6	482	15.9	0.187
4	11.061	7.9927	785	6.0	160	5.3	0.163
5	12.100	7.3086	1355	10.3	150	4.9	0.088
6	13.619	6.4964	450	3.4	89	2.9	0.157
7	17.677	5.0132	753	5.7	126	4.2	0.134
8	18.180	4.8755	2011	15.3	588	19.4	0.234
9	20.840	4.2588	439	3.3	40	1.3	0.072
10	21.334	4.1615	427	3.2	67	2.2	0.125

Claim 9 (original): The crystalline compound of Claim 8 having a ^{13}C NMR (solid state) in ppm of: 189.9; 186.7; 71.6; 58.5; 43.2; 29.9; 23.5.

Claim 10 (currently amended): ~~The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt, ethyl alcohol solvate, crystalline compound of~~
Claim 8 having a ^{13}C NMR peak at 58.5 ppm.

Claim 11 (cancelled): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid mono-calcium salt methanol solvate.

Claim 12 (currently amended): ~~The crystalline compound of Claim 11, 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid mono-calcium salt methanol solvate~~
having an x-ray powder diffraction pattern substantially comprising:

Appl. No. 10/018,617
 Amdt. dated
 Reply to Office Action of May 7, 2003

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.896	12.8072	11991	100.0	2593	100.0	0.173
2	8.339	10.5940	2046	17.1	334	12.9	0.131
3	9.219	9.5853	1438	12.0	281	10.8	0.156
4	10.280	8.5979	632	5.3	180	6.9	0.227
5	11.320	7.8105	1079	9.0	322	12.4	0.238
6	15.800	5.6044	463	3.9	59	2.3	0.102
7	16.741	5.2913	432	3.6	38	1.4	0.069
8	18.160	4.8809	1260	10.5	599	23.1	0.380
9	18.702	4.7408	700	5.8	184	7.1	0.210
10	19.816	4.4766	589	4.9	94	3.6	0.127
11	21.724	4.0876	510	4.3	96	3.7	0.150

Claim 13 (original): The crystalline compound of Claim 12 having a ^{13}C NMR (solid state) in ppm of: 189.6; 186.2; 71.4; 43.2; 29.6; 23.5.

Claim 14 (cancelled): The compound which is 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-propyl alcohol solvate.

Claim 15 (original): The crystalline compound of ~~Claim 14~~ 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-propyl alcohol solvate having an x-ray powder diffraction pattern substantially comprising:

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.899	12.8025	12371	100.0	3495	100.0	0.226
2	7.843	11.2637	4815	38.9	1119	32.0	0.186
3	8.661	10.2009	1709	13.8	357	10.2	0.167
4	11.359	7.7833	771	6.2	141	4.0	0.146
5	12.300	7.1900	752	6.1	127	3.6	0.135
6	13.100	6.7528	517	4.2	37	1.0	0.057
7	18.262	4.8540	1945	15.7	596	17.1	0.245
8	20.721	4.2832	828	6.7	279	8.0	0.269
9	21.740	4.0847	573	4.6	146	4.2	0.203

Appl. N . 10/018,617

Amdt. dated

Reply to Office Action of May 7, 2003

Claim 16 (currently amended): The crystalline compound of Claim 15 having a ^{13}C NMR (solid state) in ppm of: 189.6; ~~186.2; 71.4; 186.0; 71.6;~~ 43.2; 29.6; ~~23.5~~ 23.8.

Claim 17 (cancelled): The compound which is 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid mono-calcium salt 2-propyl alcohol solvate.

Claim 18 (currently amended): The crystalline compound of ~~Claim 17~~ 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid mono-calcium salt 2-propyl alcohol solvate having an x-ray powder diffraction pattern substantially comprising:

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.918	12.7674	10028	100.0	2562	100.0	0.204
2	8.000	11.0427	3984	39.7	800	31.2	0.161
3	8.619	10.2506	1619	16.1	346	13.5	0.171
4	11.338	7.7981	658	6.6	68	2.6	0.082
5	11.718	7.5459	236	2.4	28	1.1	0.093
6	12.241	7.2243	761	7.6	131	5.1	0.138
7	15.382	5.7557	610	6.1	107	4.2	0.140
8	18.162	4.8803	1937	19.3	441	17.2	0.182
9	20.779	4.2713	853	8.5	222	8.6	0.208

Claim 19 (original): The crystalline compound of Claim ~~14~~ 18 having a ^{13}C NMR (solid state) in ppm of: 189.4; 187.7; 70.9; 69.4; 66.5; 63.8; 43.2; 35.0; 30.1; 23.8; 18.7; 14.3.

Claim 20 (currently amended): The ~~compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 2-propyl alcohol solvate~~ crystalline compound of Claim 18 having a ^{13}C NMR peak at 63.8, 18.7, or 14.3 ppm.

Claim 21 (cancelled): The compound which is 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-butyl alcohol solvate.

Appl. No. 10/018,617

Amdt. dated

Reply to Office Action of May 7, 2003

Claim 22 (currently amended): The crystalline compound of ~~Claim 21~~ 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-butyl alcohol solvate having an x-ray powder diffraction pattern substantially comprising:

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	7.060	12.5101	19609	100.0	4796	100.0	0.196
2	9.078	9.7332	3027	15.4	567	11.8	0.150
3	11.100	7.9644	924	4.7	164	3.4	0.142
4	16.361	5.4135	554	2.8	76	1.6	0.109
5	18.040	4.9133	2276	11.6	456	9.5	0.160
6	18.820	4.7112	1303	6.6	385	8.0	0.236
7	19.922	4.4532	1886	9.6	457	9.5	0.193
8	21.560	4.1183	853	4.4	205	4.3	0.191
9	22.281	3.9867	343	1.7	37	0.8	0.086
10	23.521	3.7793	450	2.3	107	2.2	0.189

Claim 23 (currently amended): The crystalline compound of Claim ~~21~~ 22 having a ^{13}C NMR (solid state) in ppm of: 189.9; 186.0; 71.6; 43.2; 29.9; 23.8.

Claim 24 (currently amended): The compound ~~6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic~~ 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 2 having an x-ray powder diffraction pattern substantially comprising:

Appl. No. 10/018,617

Amdt. dated

Reply to Office Action of May 7, 2003

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	7.259	12.1686	9283	100.0	2482	100.0	0.214
2	8.739	10.1100	4191	45.1	603	24.3	0.115
3	9.386	8.9628	967	10.4	161	6.5	0.133
4	11.659	7.5838	430	4.6	49	1.9	0.089
5	13.955	6.3408	305	3.3	58	2.3	0.151
6	14.220	6.2233	326	3.5	73	2.9	0.178
7	15.387	5.7537	278	3.0	19	0.7	0.053
8	16.461	5.3806	986	10.6	187	7.5	0.152
9	17.361	5.1039	1490	16.1	348	14.0	0.187
10	18.063	4.9069	1284	13.8	323	13.0	0.201
11	19.302	4.5947	871	9.4	166	6.7	0.152
12	19.862	4.4664	686	7.4	142	5.7	0.166
13	20.200	4.3923	457	4.9	103	4.1	0.179
14	21.178	4.1918	656	7.1	97	3.9	0.117
15	21.641	4.1031	167	1.8	6	0.2	0.029
16	22.300	3.9833	794	8.6	192	7.7	0.193
17	23.218	3.8278	247	2.7	23	0.9	0.071
18	24.100	3.6897	183	2.0	34	1.3	0.145
19	25.481	3.4928	487	5.2	141	5.7	0.231
20	28.800	3.0974	134	1.4	14	0.6	0.083
21	29.297	3.0459	259	2.8	28	1.1	0.084
22	30.700	2.9099	287	3.1	20	0.8	0.055


Claim 25 (original): The crystalline compound of Claim 24 having a ^{13}C NMR (solid state) in ppm of 190.9; 189.6; 186.2; 120.4; 72.7; 44.7; 44.2; 43.0; 42.3; 39.3; 37.9; 31.8; 30.9; 29.6; 27.7; 26.2; 25.3; 24.0; 22.9; 21.5; and 20.2.

Claim 26 (currently amended): The compound ~~6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 2~~ crystalline compound of Claim 16 having a ^{13}C NMR peak at 72.7, 44.7, or 26.2 ppm.


Claim 27 (currently amended): The compound of Claim + 4, wherein said crystalline structure contains from approximately 0.1 to approximately 1.0 water molecules per salt ion.

Claim 28 (original): A method for preparing a stable crystalline compound of Formula II:

Appl. No. 10/018,617
 Amdt. dated
 Reply to Office Action of May 7, 2003



wherein R₁ is lower alkyl and x is a number from 0 to 10, comprising reacting a compound of Formula I



with calcium oxide in an alkanol organic solvent of the formula R₁OH to yield a solid product; and drying the solid product to obtain the monocalcium dicarboxylate ether salt of the compound of Formula II having a stoichiometric ratio of calcium to dicarboxylate of approximately 1:1.

Claim 29 (original): The method of Claim 28, wherein the organic solvent is a C₁-C₁₂ alcohol.

Claim 30 (original): The method of Claim 28, wherein the C₁-C₁₂ alcohol is essentially anhydrous.

Claim 31 (original): The method of Claim 28, wherein the alcohol is a C₁-C₄ alkanol.

Claim 32 (original): The method of Claim 28 further comprising the step of introducing a work-up solvent into the organic alcohol solvent, wherein the work-up solvent causes at least a portion of the monocalcium dicarboxylate ether salt to precipitate from the organic alcohol solvent.


Appl. No. 10/018,617
 Amdt. dated
 Reply to Office Action of May 7, 2003

Claim 33 (original): The method of Claim 32 wherein the work-up solvent is methyl *tert*-butyl ether.

Claim 34 (original): The method of Claim 32 further comprising the step of filtering the solid product from the organic solvent prior to drying.

Claim 35 (original): The method of Claim 32 further comprising the step of washing the solid product with the organic work-up solvent subsequent to filtering.

Claim 36 (original): A method for preparing a crystalline hydrate of the Formula II



wherein R₁ is H and x is a number from 0 to 10, comprising reacting an alcohol solvate of Formula II where R₁ is lower alkyl with water.

Claim 37 (original): The method of Claim 36 wherein the solid product contains between approximately 0.1 and approximately 1.0 equivalents of water per equivalent of the monocalcium dicarboxylate ether salt subsequent to said filtering step and said drying step.

Claim 38 (currently amended): The method of Claim 28 wherein said reacting step occurs at a temperature between about ~~15°C~~ 25°C and the reflux point of the alkanol organic solvent at standard pressure.

Claim 39 (original): The method of Claim 28 wherein said reacting step occurs at a temperature between the reflux point of the alkanol organic solvent and about 150°C at a pressure above standard pressure.

Appl. No. 10/018,617
Amdt. dated
Reply to Office Action of May 7, 2003

Claim 40 (original): A method of converting the compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt hydrate Crystal Form 1 into the compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt hydrate Crystal Form 2, said method comprising the steps of: exposing the Crystal Form 1 to water; agitating the Crystal Form 1 and water; heating the Crystal Form 1 and water for sufficient time for a conversion to occur so as to yield Crystal Form 2; and drying the solid product to obtain the 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid monocalcium salt hydrate Crystal Form 2, wherein the Crystal Form 2 has a stoichiometric ratio of calcium to dicarboxylate form of the compound of 1:1.

Claim 41 (original): The method of Claim 40 further comprising the step of filtering the Crystal Form 2 from the water prior to said drying step.

Claim 42 (cancelled): A pharmaceutical composition comprising the compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt together with one or more pharmaceutically acceptable diluents, carriers or excipients.

Claim 43 (cancelled): A pharmaceutical composition comprising a crystalline form 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt together with one or more pharmaceutically acceptable diluents, carriers or excipients.

Claim 44 (original): A pharmaceutical composition comprising 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt hydrate Crystal Form 1 together with one or more pharmaceutically acceptable diluents, carriers or excipients.

Claim 45 (original): A pharmaceutical composition comprising 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt hydrate Crystal Form 2 together with one or more pharmaceutically acceptable diluents, carriers or excipients.

Appl. No. 10/018,617
Amdt. dated
Reply to Office Action of May 7, 2003

Claim 46 (currently amended): ~~The use of~~ A method of treating diabetes in a patient in need thereof, said method comprising administering to the patient a therapeutically effective amount of a compound as set forth in Claim ~~1~~ 4 ~~for the treatment of vascular disease.~~

Claim 47 (currently amended): ~~The use of~~ A method of treating diabetes in a patient in need thereof, said method comprising administering to the patient a therapeutically effective amount of a compound as set forth in Claim ~~1~~ 24 ~~for the treatment of diabetes.~~

Claim 48 (cancelled): A compound according to Claim 1 substantially as described herein in any of the examples.

Claim 49 (cancelled): A method of treating a vascular disease in a patient in need thereof, said method comprising administering to the patient a therapeutically effective amount of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt.

Claim 50 (currently amended): A method ~~according to Claim 49, wherein the compound is~~ of treating a vascular disease in a patient in need thereof, said method comprising administering to the patient a therapeutically effective amount of a compound as set forth in Claim 4. ~~Form I having an x-ray powder diffraction pattern substantially comprising:~~

Appl. No. 10/018,617

Amtd. dated

Reply to Office Action of May 7, 2003

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	6.760	13.0648	5106	100.0	1497	100.0	0.234
2	8.183	10.7953	1743	34.1	435	29.1	0.200
3	8.560	10.3207	1866	36.5	543	36.3	0.233
4	9.239	9.5638	234	4.6	29	1.9	0.096
5	9.760	9.0546	972	19.0	220	14.7	0.181
6	10.569	8.3634	156	3.1	12	0.8	0.061
7	11.141	7.9353	178	3.5	29	1.9	0.130
8	13.760	6.4304	266	5.2	46	3.1	0.138
9	15.599	5.6761	338	6.6	63	4.2	0.148
10	16.740	5.2917	433	8.5	64	4.3	0.118
11	17.420	5.0866	1890	37.0	689	46.0	0.291
12	20.639	4.3000	523	10.2	128	8.5	0.196
13	21.391	4.1505	188	3.7	20	1.3	0.085
14	22.139	4.0119	445	8.7	74	4.9	0.132
15	31.559	2.8326	270	5.3	24	1.6	0.070

Claim 51 (currently amended): A method according to Claim 49, wherein the compound is of treating a vascular disease in a patient in need thereof, said method comprising administering to the patient a therapeutically effective amount of a compound as set forth in Claim 24. ~~Crystal Form 2 having an x-ray powder diffraction pattern substantially comprising:~~

Appl. No. 10/018,617

Amdt. dated

Reply to Office Action of May 7, 2003

#	2-Theta	d(A)	Peak	P%	Area	Area%	FWHM
1	7.259	12.1686	9283	100.0	2482	100.0	0.214
2	8.739	10.1100	4191	45.1	603	24.3	0.115
3	9.3860	8.9628	967	10.4	161	6.5	0.133
4	11.659	7.5838	430	4.6	49	1.9	0.089
5	13.955	6.3408	305	3.3	58	2.3	0.151
6	14.220	6.2233	326	3.5	73	2.9	0.178
7	15.387	5.7537	278	3.0	19	0.7	0.053
8	16.461	5.3806	986	10.6	187	7.5	0.152
9	17.361	5.1039	1490	16.1	348	14.0	0.187
10	18.063	4.9069	1284	13.8	323	13.0	0.201
11	19.302	4.5947	871	9.4	166	6.7	0.152
12	19.862	4.4664	686	7.4	142	5.7	0.166
13	20.200	4.3923	457	4.9	103	4.1	0.179
14	21.178	4.1918	656	7.1	97	3.9	0.117
15	21.641	4.1031	167	1.8	6	0.2	0.029
16	22.300	3.9833	794	8.6	192	7.7	0.193
17	23.218	3.8278	247	2.7	23	0.9	0.071
18	24.100	3.6897	183	2.0	34	1.3	0.145
19	25.481	3.4928	487	5.2	141	5.7	0.231
20	28.800	3.0974	134	1.4	14	0.6	0.083
21	29.297	3.0459	259	2.8	28	1.1	0.084
22	30.700	2.9099	287	3.1	20	0.8	0.055

Claim 52 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 1 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2 θ at 6.760.

Claim 53 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 1 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2 θ at 17.420.

Claim 54 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 1 that exhibits an x-ray powder diffraction pattern comprising characteristic peaks expressed in degrees 2 θ at 6.760 and 17.420.

Appl. No. 10/018,617
Amdt. dated
Reply to Office Action of May 7, 2003

Claim 55 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 1 according to claim 54 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2 θ at 8.183.

Claim 56 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 1 according to claim 54 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2 θ at 8.560.

Claim 57 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 1 according to claim 54 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2 θ at 9.760.

Claim 58 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 1 according to claim 54 that exhibits an x-ray powder diffraction pattern comprising at least one peak expressed in degrees 2 θ at 8.183, 8.560, 9.239, 9.760, 10.569, 11.141, 13.760, 15.599, 16.740, 20.639, 21.391, 22.139, or 31.559.

Claim 59 (previously added): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt ethanol solvate that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2 θ at 6.899.

Claim 60 (previously added): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt ethanol solvate that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2 θ at 8.261.

Claim 61 (previously added): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt ethanol solvate that exhibits an x-ray powder

Appl. No. 10/018,617
Amdt. dated
Reply to Office Action of May 7, 2003

diffraction pattern comprising characteristic peaks expressed in degrees 2θ at 6.899 and 8.261.

Claim 62 (previously added): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt ethanol solvate according to claim 61 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 8.838.

Claim 63 (previously added): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt ethanol solvate according to claim 61 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 18.180.

Claim 64 (previously added): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt ethanol solvate according to claim 61 that exhibits an x-ray powder diffraction pattern comprising at least one peak expressed in degrees 2θ at 8.838, 11.061, 12.100, 13.619, 17.677, 18.180, 20.840, or 21.334.

Claim 65 (previously added): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid mono-calcium salt methanol solvate that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 6.896.

Claim 66 (previously added): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid mono-calcium salt methanol solvate that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 18.160.

Claim 67 (previously added): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid mono-calcium salt methanol solvate that exhibits an x-ray powder diffraction pattern comprising characteristic peaks expressed in degrees 2θ at 6.896 and 18.160.

Appl. No. 10/018,617
Amdt. dated
Reply to Office Action of May 7, 2003

Claim 68 (previously added): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid mono-calcium salt methanol solvate according to claim 67 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 8.339.

Claim 69 (previously added): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid mono-calcium salt methanol solvate according to claim 67 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 9.219.

Claim 70 (previously added): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid mono-calcium salt methanol solvate according to claim 67 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 11.320.

Claim 71 (previously added): The crystalline compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid mono-calcium salt methanol solvate according to claim 67 that exhibits an x-ray powder diffraction pattern comprising at least one peak expressed in degrees 2θ at 8.339, 9.219, 10.280, 11.320, 15.800, 16.741, 18.702, 19.816, or 21.724.

Claim 72 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-propyl alcohol solvate that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 6.899.

Claim 73 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-propyl alcohol solvate that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 7.843.

Claim 74 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-propyl alcohol solvate that exhibits an

Appl. No. 10/018,617

Amtdt. dated

Reply to Office Action of May 7, 2003

x-ray powder diffraction pattern comprising characteristic peaks expressed in degrees 2θ at 6.899 and 7.843.

Claim 75 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-propyl alcohol solvate according to claim 74 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 8.661.

Claim 76 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-propyl alcohol solvate according to claim 74 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 18.262.

Claim 77 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-propyl alcohol solvate according to claim 74 that exhibits an x-ray powder diffraction pattern comprising at least one peak expressed in degrees 2θ at 8.661, 11.359, 12.300, 13.100, 18.262, 20.721, or 21.740.

Claim 78 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 2-propyl alcohol solvate that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 6.918.

Claim 79 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 2-propyl alcohol solvate that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 8.000.

Claim 80 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 2-propyl alcohol solvate that exhibits an x-ray powder diffraction pattern comprising characteristic peaks expressed in degrees 2θ at 6.918 and 8.000.

Appl. No. 10/018,617

Amdt. dated

Reply to Office Action f May 7, 2003

Claim 81 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 2-propyl alcohol solvate according to claim 80 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 8.619.

Claim 82 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 2-propyl alcohol solvate according to claim 80 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 18.162.

Claim 83 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 2-propyl alcohol solvate according to claim 80 that exhibits an x-ray powder diffraction pattern comprising at least one peak expressed in degrees 2θ at 8.619, 11.338, 11.718, 12.241, 15.382, 18.162, or 20.779.

Claim 84 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-butyl alcohol solvate that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 7.060

Claim 85 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-butyl alcohol solvate that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 9.078.

Claim 86 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-butyl alcohol solvate that exhibits an x-ray powder diffraction pattern comprising characteristic peaks expressed in degrees 2θ at 7.060 and 9.078.

Claim 87 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-butyl alcohol solvate according to claim

Appl. No. 10/018,617
Amdt. dated
Reply to Office Action of May 7, 2003

86 that exhibits an x-ray powder diffraction pattern comprising at least one peak expressed in degrees 2θ at 11.100, 16.361, 18.040, 18.820, 19.922, 21.560, 22.281, or 23.521.

Claim 88 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 2 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 7.259.

Claim 89 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 2 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 8.739

Claim 90 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 2 that exhibits an x-ray powder diffraction pattern comprising characteristic peaks expressed in degrees 2θ at 7.259 and 8.739.

Claim 91 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 2 according to claim 90 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 17.361.

Claim 92 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 2 according to claim 90 that exhibits an x-ray powder diffraction pattern comprising a characteristic peak expressed in degrees 2θ at 18.063.

Claim 93 (previously added): The compound 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt Crystal Form 2 according to claim 90 that exhibits an x-ray powder diffraction pattern comprising at least one peak expressed in degrees 2θ at 9.386, 11.659, 13.955, 14.220, 15.387, 16.461, 17.361, 18.063, 19.302,

Appl. No. 10/018,617
Amdt. dated
Reply to Office Action of May 7, 2003

19.862, 20.200, 21.178, 21.641, 22.300, 23.218, 24.100, 25.481, 28.800, 29.297, or
30.700.